SummaryCell banking, disease modeling, and cell therapy applications have placed increasing demands on hiPSC technology. Specifically, the high-throughput derivation of footprint-free hiPSCs and their expansion in systems that allow scaled production remains technically challenging. Here, we describe a platform for the rapid, parallel generation, selection, and expansion of hiPSCs using small molecule pathway inhibitors in stage-specific media compositions. The platform supported efficient and expedited episomal reprogramming using just OCT4/SOX2/SV40LT combination (0.5%–4.0%, between days 12 and 16) in a completely feeder-free environment. The resulting hiPSCs are transgene-free, readily cultured, and expanded as single cells while maintai...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...
SummaryCell banking, disease modeling, and cell therapy applications have placed increasing demands ...
AbstractLarge-scale production of human induced pluripotent stem cells (hiPSCs) by robust and econom...
AbstractThere are two critical stages in the retroviral reprogramming of somatic cells to produce hu...
Background: Disease modeling with patient-derived induced pluripotent stem cells (iPSCs) is a powerf...
SummaryDirect reprogramming of human fibroblasts to a pluripotent state has been achieved through ec...
International audienceHuman induced pluripotent stem (hiPS) cell technology has already revolutioniz...
International audienceHuman induced pluripotent stem (hiPS) cell technology has already revolutioniz...
AbstractLarge-scale production of human induced pluripotent stem cells (hiPSCs) by robust and econom...
Genetic reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) could offer r...
AbstractHerein, we describe a modified protocol for the generation of human induced pluripotent stem...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...
SummaryCell banking, disease modeling, and cell therapy applications have placed increasing demands ...
AbstractLarge-scale production of human induced pluripotent stem cells (hiPSCs) by robust and econom...
AbstractThere are two critical stages in the retroviral reprogramming of somatic cells to produce hu...
Background: Disease modeling with patient-derived induced pluripotent stem cells (iPSCs) is a powerf...
SummaryDirect reprogramming of human fibroblasts to a pluripotent state has been achieved through ec...
International audienceHuman induced pluripotent stem (hiPS) cell technology has already revolutioniz...
International audienceHuman induced pluripotent stem (hiPS) cell technology has already revolutioniz...
AbstractLarge-scale production of human induced pluripotent stem cells (hiPSCs) by robust and econom...
Genetic reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) could offer r...
AbstractHerein, we describe a modified protocol for the generation of human induced pluripotent stem...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
Data suggest that clinical applications of human induced pluripotent stem cells (hiPSCs) will be rea...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...
En 2006 et 2007, les équipes de Yamanaka et Thomson réalisent la reprogrammation de cellules somatiq...